In Memoriam: Hartmut Derendorf (1953–2020).
- Published in:
- 2021
- By:
- Publication type:
- Obituary
Works matching IS 2160763X AND DT 2021 AND VI 10 AND IP 4
Results: 12
1
2
First‐in‐Human Study for a Selective Rearranged During Transfection Tyrosine Kinase Inhibitor, GSK3352589, to Investigate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 4, p. 334, doi. 10.1002/cpdd.911
- By:
- Publication type:
- Article
3
Pharmacokinetic and Pharmacodynamic Target Attainment in Adult and Pediatric Patients Following Administration of Ceftaroline Fosamil as a 5‐Minute Infusion.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 4, p. 420, doi. 10.1002/cpdd.907
- By:
- Publication type:
- Article
4
Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 4, p. 393, doi. 10.1002/cpdd.874
- By:
- Publication type:
- Article
5
Lack of Drug‐Drug Interaction Between Filgotinib, a Selective JAK1 Inhibitor, and Oral Hormonal Contraceptives Levonorgestrel/Ethinyl Estradiol in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 4, p. 376, doi. 10.1002/cpdd.870
- By:
- Publication type:
- Article
6
A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, 4‐Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 4, p. 404, doi. 10.1002/cpdd.867
- By:
- Publication type:
- Article
7
Bioequivalence Analysis of 2 Dapoxetine Hydrochloride Formulations in Healthy Chinese Male Volunteers Under Fed and Fasting Conditions: A Randomized, Open‐Label, 2‐Sequence, 2‐Period, 2‐Way Crossover Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 4, p. 384, doi. 10.1002/cpdd.866
- By:
- Publication type:
- Article
8
In Vitro Dissolution and In Vivo Bioequivalence Evaluation of Two Metformin Extended‐Release Tablets.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 4, p. 414, doi. 10.1002/cpdd.857
- By:
- Publication type:
- Article
9
Biosimilarity Assessment of 2 Filgrastim Therapeutics in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 4, p. 346, doi. 10.1002/cpdd.856
- By:
- Publication type:
- Article
10
Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist Apararenone in Healthy Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 4, p. 353, doi. 10.1002/cpdd.855
- By:
- Publication type:
- Article
11
Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 4, p. 366, doi. 10.1002/cpdd.850
- By:
- Publication type:
- Article
12
Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2021, v. 10, n. 4, p. 327, doi. 10.1002/cpdd.711
- Publication type:
- Article